We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-14.95%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.72B
AUM Growth
-$950M
Cap. Flow
-$368M
Cap. Flow %
-21.39%
Top 10 Hldgs %
48.56%
Holding
373
New
67
Increased
88
Reduced
111
Closed
78

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$59.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$32.9M
3
AMGN icon
Amgen
AMGN
+$18M
4
LLY icon
Eli Lilly
LLY
+$15.9M
5
BMY icon
Bristol-Myers Squibb
BMY
+$7.23M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$6.04M
2
ABT icon
Abbott
ABT
+$4.77M
3
RGNX icon
Regenxbio
RGNX
+$4.1M
4
CELG
Celgene Corp
CELG
+$3.94M
5
UTHR icon
United Therapeutics
UTHR
+$3.59M

Sector Composition

Rank Sector Weight
1 Healthcare 17.88%
2 Financials 0.23%
3 Consumer Staples 0.05%
4 Technology 0.03%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IONS icon
51
CALL
Ionis Pharmaceuticals
IONS
$9.14B
$5.04M 0.29%
1,054
-1,117
-51% -$44.2K
ACOR
52
DELISTED
Acorda Therapeutics
ACOR
$4.96M 0.29%
+2,200
New +$5.23M
ALNY icon
53
CALL
Alnylam Pharmaceuticals
ALNY
$38.5B
$4.64M 0.27%
1,240
-208
-14% -$8.71K
SGYPW
54
CALL
DELISTED
Synergy Pharmaceuticals, Inc. - Warrants
SGYPW
$4.59M 0.27%
7,536
-376
-5% -$134
RDUS
55
PUT
DELISTED
Radius Health, Inc.
RDUS
$4.53M 0.26%
1,190
+1,049
+744% +$49.9K
HZNP
56
PUT
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$4.52M 0.26%
2,791
+2,328
+503% +$42.2K
NBIX icon
57
CALL
Neurocrine Biosciences
NBIX
$18.4B
$4.46M 0.26%
1,153
-61
-5% -$2.76K
AMGN icon
58
CALL
Amgen
AMGN
$212B
$4.4M 0.26%
+301
New +$45.3K
SAGE
59
CALL
DELISTED
Sage Therapeutics
SAGE
$4.33M 0.25%
849
-316
-27% -$14.9K
ACHN
60
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
$4.17M 0.24%
10,087
+1,048
+12% +$5.57K
PTLA
61
CALL
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$4.05M 0.24%
1,803
+1,503
+501% +$29.4K
MDCO
62
PUT
DELISTED
Medicines Co
MDCO
$3.98M 0.23%
1,172
+1,072
+1,072% +$38K
BNBX
63
DELISTED
BNB PLUS CORP
BNBX
$3.9M 0.23%
+4
New +$5.95M
STML
64
DELISTED
Stemline Therapeutics, Inc.
STML
$3.83M 0.22%
357,806
+259,756
+265% +$3.14M
MDCO
65
DELISTED
Medicines Co
MDCO
$3.81M 0.22%
112,392
+98,884
+732% +$3.51M
AMRN
66
CALL
Amarin Corp
AMRN
$293M
$3.8M 0.22%
617
-65
-10% -$4.13K
UTHR icon
67
CALL
United Therapeutics
UTHR
$26.1B
$3.77M 0.22%
+263
New +$33.6K
LJPC
68
DELISTED
La Jolla Pharmaceutical Company
LJPC
$3.7M 0.22%
210,978
+90,014
+74% +$1.73M
BLUE
69
CALL
DELISTED
bluebird bio
BLUE
$3.67M 0.21%
46
-61
-57% -$48.4K
IONS icon
70
PUT
Ionis Pharmaceuticals
IONS
$9.14B
$3.52M 0.21%
737
– –
MON
71
CALL
DELISTED
Monsanto Co
MON
$3.29M 0.19%
313
-5,294
-94% -$543K
SIOX
72
PUT
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$3.28M 0.19%
+330
New +$34.8K
BIIB icon
73
CALL
Biogen
BIIB
$30.4B
$3.26M 0.19%
115
-552
-83% -$164K
PBYI icon
74
Puma Biotechnology
PBYI
$406M
$3.17M 0.18%
+103,243
New +$4.46M
CDTX
75
DELISTED
Cidara Therapeutics
CDTX
$3.04M 0.18%
14,620
+5,102
+54% +$1.06M
1 2
3
4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2016 Portfolio in Review

As of Q4 2016, Sabby Management held 373 positions worth $1.72B, down 36% from $2.67B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Sabby Management withdrew a net $368M in Q4 2016, closing 78 positions and reducing 111 holdings. Its most notable exit was Shire pic, an estimated $6.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 9.2% a quarter earlier, followed by Financials and Consumer Staples.

Against the trend, Sabby Management opened a new position in Eli Lilly worth $15.7M.

  • Sabby Management's largest Q4 2016 buy was Eli Lilly: 213,113 shares worth $15.7M.
  • Sabby Management added most to Sarepta Therapeutics in Q4 2016, an estimated $59.4M increase.
  • Sabby Management's biggest Q4 2016 reduction was Regenxbio, cutting an estimated $4.1M.
  • Sabby Management fully exited Shire pic in Q4 2016, selling an estimated $6.04M.
  • Sabby Management's ten largest holdings make up 49% of its $1.72B portfolio in Q4 2016.
  • Sabby Management opened 67 new positions and closed 78 in Q4 2016.
  • Sabby Management's portfolio value fell 36% quarter-over-quarter to $1.72B.

Based on Sabby Management's 13F filing for Q4 2016, filed 14 Feb 2017.